Human Papillomavirus Infection

Pipeline Programs

Companies

Clinical Trials

1 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine

7100%

+ 26 programs with unclassified modality

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

MSDIreland - Ballydine

7 programs

Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine AdsorbedPhase 4Vaccine1 trial

GardasilPhase 41 trial

V503Phase 31 trial

ComplianceN/A1 trial

+2 more programs

Active Trials

NCT01087164Unknown600Est. Jun 2014

NCT00932009Completed1,933Est. Dec 2009

NCT00572832Completed200Est. Aug 2009

+4 more trials

Sharp TherapeuticsPA - Pittsburgh

7 programs

Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine AdsorbedPhase 4Vaccine

GardasilPhase 4

V503Phase 3

ComplianceN/A

+2 more programs

Merck & Co.RAHWAY, NJ

3 programs

Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine AdsorbedPhase 4Vaccine

Quadrivalent human papillomavirus vaccine on-time administrationN/AVaccine

offer of vaginal self collectionPHASE_2_31 trial

Active Trials

NCT01095198Unknown1,440Est. Jan 2013

Guard TherapeuticsSweden - Stockholm

4 programs

Nonavalent HPV study vaccinePhase 3Vaccine1 trial

Recombinant NonavalentPhase 31 trial

Recombinant NonavalentPhase 11 trial

Active Trials

NCT05680454Completed160Est. May 2022

NCT06207175Unknown1,260Est. Jan 2026

NCT05668572Unknown12,000Est. Feb 2023

+1 more trials

Antiva BiosciencesCA - Redwood City

1 program

ABI-2280Phase 1/21 trial

Active Trials

NCT06491446Completed141Est. Apr 2026

BravoVaxChina - Wuhan

1 program

Human papillomavirusPhase 11 trial

Active Trials

NCT05672966Unknown40Est. Oct 2024

GSKLONDON, United Kingdom

4 programs

Cervarix data collectionN/A1 trial

Endocervical samplesN/A1 trial

Prevalence-based modelN/A1 trial

Active Trials

NCT01551537Withdrawn0Est. Apr 2014

NCT01205412Completed552Est. Nov 2011

NCT01158209Completed490Est. Aug 2011

+1 more trials

ViiV HealthcareNC - Durham

4 programs

Cervarix data collectionN/A

Endocervical samplesN/A

Prevalence-based modelN/A

Geneva BiotechSwitzerland - Pregny-Chambésy

1 program

HPV testingN/A1 trial

Active Trials

NCT07550010Recruiting1,800Est. Sep 2027

Angeles TherapeuticsCA - Los Angeles

1 program

Parent RemindersN/A1 trial

Active Trials

NCT03726151Completed17,000Est. May 2024

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

2031

MSDDiphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed

MSDGardasil

Guard TherapeuticsNonavalent HPV study vaccine

Guard TherapeuticsRecombinant Nonavalent

MSDV503

Merck & Co.offer of vaginal self collection

Antiva BiosciencesABI-2280

BravoVaxHuman papillomavirus

Guard TherapeuticsRecombinant Nonavalent

Geneva BiotechHPV testing

Angeles TherapeuticsParent Reminders

GSKCervarix data collection

GSKEndocervical samples

Showing 15 of 20 trials with date data

Clinical Trials (20)

Total enrollment: 57,026 patients across 20 trials

NCT07706673 MSDDiphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed

ESCUDDO Long Term Follow Up

Start: Aug 2026Est. completion: Jan 203113,700 patients

Phase 4Enrolling By Invitation

NCT00925288 MSDGardasil

Acceptability of Human Papillomavirus (HPV) Vaccine in Female Sex Workers

Start: Oct 2009Est. completion: Aug 2011200 patients

Phase 4Completed

NCT06207175 Guard TherapeuticsNonavalent HPV study vaccine

A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine

Start: Nov 2023Est. completion: Jan 20261,260 patients

Phase 3Unknown

NCT05662020 Guard TherapeuticsRecombinant Nonavalent

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Start: Mar 2022Est. completion: Mar 20282,750 patients

Phase 3Active Not Recruiting

NCT05668572 Guard TherapeuticsRecombinant Nonavalent

A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine

Start: Dec 2020Est. completion: Feb 202312,000 patients

Phase 3Unknown

NCT01984697 MSDV503

A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)

Start: Dec 2013Est. completion: Jul 20171,518 patients

Phase 3Completed

NCT00988884 MSDV503

A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)

Start: Oct 2009Est. completion: Feb 20111,241 patients

Phase 3Completed

NCT01095198 Merck & Co.offer of vaginal self collection

Randomized Trial of Vaginal Self Sampling for Human Papillomavirus (HPV)

Start: Apr 2010Est. completion: Jan 20131,440 patients

Phase 2/3Unknown

NCT06491446 Antiva BiosciencesABI-2280

Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts

Start: Mar 2024Est. completion: Apr 2026141 patients

Phase 1/2Completed

NCT05672966 BravoVaxHuman papillomavirus

Phase I Clinical Trial of a Candidate HPV Vaccine

Start: Aug 2023Est. completion: Oct 202440 patients

Phase 1Unknown

NCT05680454 Guard TherapeuticsRecombinant Nonavalent

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

Start: Sep 2019Est. completion: May 2022160 patients

Phase 1Completed

NCT07550010 Geneva BiotechHPV testing

Digital Telecytology for Triage of HPV-Positive Women in Cameroon

Start: Sep 2025Est. completion: Sep 20271,800 patients

N/ARecruiting

NCT03726151 Angeles TherapeuticsParent Reminders

Comparative Effectiveness of System Interventions to Increase HPV Vaccine Receipt in FQHCs

Start: May 2018Est. completion: May 202417,000 patients

N/ACompleted

NCT01551537 GSKCervarix data collection

Post-marketing Surveillance of GSK Biologicals' Cervarix™ When Administered to Healthy Females in Sri Lanka

Start: Apr 2013Est. completion: Apr 20140

N/AWithdrawn

NCT01205412 GSKEndocervical samples

An Observational Study on the Prevalence of Human Papillomavirus Types in Women in the Kingdom of Bahrain

Start: Oct 2010Est. completion: Nov 2011552 patients

N/ACompleted

NCT01158209 GSKEndocervical samples

An Observational, Epidemiological Study on the Prevalence of Human Papillomavirus Types in Women in Egypt

Start: Oct 2010Est. completion: Aug 2011490 patients

N/ACompleted

NCT01087164 MSDCompliance

Brief Interventions to Increase HPV Vaccine Acceptance in School-based Health Centers

Start: Sep 2010Est. completion: Jun 2014600 patients

N/AUnknown

NCT01702337 GSKPrevalence-based model

Prevalence-based Health and Economic Model of the Bivalent Versus the Quadrivalent Human Papillomavirus (HPV) Vaccine

Start: Feb 2010Est. completion: Feb 20101 patients

N/ACompleted

NCT00932009 MSDPrevalence and Type Distribution of Human Papillomavirus (HPV) in Tanzanian Men

Prevalence and Type Distribution of Human Papillomavirus (HPV) in Tanzanian Men

Start: Mar 2009Est. completion: Dec 20091,933 patients

N/ACompleted

NCT00572832 MSDQuadrivalent human papillomavirus vaccine on-time administration

Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting

Start: Sep 2007Est. completion: Aug 2009200 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

7 late-stage (Phase 3) programs, potential near-term approvals

1 actively recruiting trials targeting 57,026 patients

10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.